Assembly Biosciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 11.07% of US listed stocks.
With a one year PEG ratio of 268.32, Assembly Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 87.31% of US stocks.
ASMB's price/sales ratio is 39.51; that's higher than the P/S ratio of 95.8% of US stocks.
Stocks that are quantitatively similar to ASMB, based on their financial statements, market capitalization, and price volatility, are APTX, FPRX, RGNX, RARE, and MEIP.
ASMB's SEC filings can be seen here. And to visit Assembly Biosciences Inc's official web site, go to www.assemblybio.com.
Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.
The Company granted Dr. Delaney non-qualified stock options to purchase 100,000 shares of the Company’s common stock with an exercise price of $20.52 per share, the closing price of Assembly’s common stock as reported by Nasdaq on May 27, 2020, and an award of 45,000 restricted stock units. The equity awards were granted as a material inducement to Dr. Delaney to accept the Company’s offer of employment as its Chief Scientific Officer, Virology.